Innovation leads development CSBIO: Net profit increased by 20.13% in the first half of the year

On August 27, the performance of Changshan Pharmaceutical’s 2021 mid-year report showed that in the first half of this year, the company achieved operating income of 1.417 billion yuan, an increase of 40.36% over the same period of the previous year; net profit attributable to shareholders of listed companies reached 157 million yuan, which was higher than the previous year. A year-on-year increase of 20.13%.
Hebei Changshan Biochemical Pharmaceutical Co., Ltd., as one of the leading enterprises in the production of heparin series drugs in China, has a complete heparin industry chain and is a high-tech enterprise with products ranging from crude heparin to low molecular weight heparin injection. While continuing to improve the existing business segments, the company also focuses on the research and development of innovative drugs, and continues to advance into the golden track of medical beauty. Products are exported to the United States, Germany, France, Italy, Spain, South Korea, Japan, Russia and other countries.
“Heparin-based products are important clinical anticoagulant raw materials, which have become a’rigorous demand’ for foreign anti-epidemics. During the spread of the new crown pneumonia epidemic around the world, the demand for products is increasing, and the international demand for low-molecular-weight heparin raw materials continues to be strong this year. The export volume has increased significantly over the same period last year.” Liang Nuo, deputy director of the comprehensive marketing department of Hebei Changshan Biochemical Pharmaceutical Co., Ltd., introduced that the next step, after the approval of the drug import port in the Zhengding area of the pilot free trade zone, the development of pharmaceutical companies It will bring new opportunities. With the help of the pilot free trade zone, the company will increase innovation and achieve high-quality development.
The Class 1 new drug ibenatide developed by Changshan Biochemical Pharmaceutical Company has now entered Phase III clinical trials
“The company attaches great importance to innovation and research and development. Our new class 1 drug ibenatide has now entered phase III clinical trials, and we have enjoyed the 2.5 million yuan of funding reward given to the new drug in the Zhengding area of the free trade trial zone for entering phase III clinical trials, which has now been credited. “Recently, Sun Peng, Dean of the Research Institute of Hebei Changshan Biochemical Pharmaceutical Co., Ltd., introduced that ibenatide is a long-acting GLP-1 receptor agonist preparation for the treatment of type 2 diabetes, a category 1.1 innovative drug, and was developed by Changshan Pharmaceutical Co., Ltd. The joint venture company “Changshan Kaijiejian” established with ConjuChem LLC of the United States, developed and developed ibenatide to extend the original once-daily dosing to once-a-week dosing, greatly reducing the inconvenience of frequent injections for diabetic patients. At present, all tasks in the Phase III clinical trial of ibenatide are proceeding smoothly. In addition to ibenatide, Changshan Pharmaceutical is also carrying out the research and development of 1.1 types of anti-tumor targeted original new drugs at the same time.
Up to now, Changshan Biochemical Pharmaceutical Co., Ltd. has 14 authorized patents such as the production process of low molecular weight heparin calcium, the preparation method of enoxaparin sodium, the preparation process of dalteparin sodium, and the process of preparing enoxaparin sodium by membrane separation. It also established the Pharmaceutical Research Institute, which is composed of the National and Local Joint Engineering Laboratory of Polysaccharide Drug Production Technology, Hebei Polysaccharide Drug Engineering Technology Research Center, small molecule drug synthesis laboratory, analysis laboratory and preparation laboratory. With a R&D team of more than 100 people and advanced equipment, it has formed a new situation of drug R&D that focuses on technological innovation and new product development. At the same time, it has 1 national-level enterprise technology innovation platform, 3 provincial-level R&D platforms, and 2 municipal-level R&D platforms.
According to the 2021 mid-year report, Changshan Pharmaceutical Co., Ltd. has achieved sales revenue and the medical aesthetics sector is actively expanding. Changshan Pharmaceutical continues to expand the scale of its hyaluronic acid and cosmetics business segments. Among them, Ecduoyin API has entered the trial production stage, and the yield level is relatively high. It is understood that the company’s “Qianjiyuan” cosmetics are constantly increasing, including hyaluronic acid, ectoine, peptides, heparin sodium, amino acids and other series of cosmetics for online sales. E-commerce operations and online sales revenue are relatively high. Great improvement. Although the company’s hyaluronic acid, Ectorin raw materials and cosmetics business still account for a small proportion of the company’s revenue, the company continues to develop and enrich product varieties, improve sales models, expand sales networks, and continue to increase the sales scale of hyaluronic acid and cosmetics. Accelerate the development of the medical aesthetics sector and help become a new growth point for future profits.

Post time: Sep-06-2021